Germantown, United States
Senseonics, Incorporated, founded in 1996, is a pioneering force in the biotechnology and medical devices industries, with a focal aim of revolutionizing diabetes management through advanced continuous glucose monitoring (CGM) technologies. Their implantable CGM systems offer individuals with diabetes enhanced confidence and control over their health, epitomizing their slogan: "Advancing the future of diabetes management through innovative technology."
Based in the United States, Senseonics thrives on collaboration and innovation. By integrating efforts across science, engineering, and clinical teams, the company addresses real-world diabetes challenges, delivering solutions with profound impact. The culture of cross-functional teamwork fuels their groundbreaking progress.
In terms of financial backing, Senseonics secured a substantial $92.00M in post-IPO debt investment on 01 May 2026, with financing led by Barclays, Lake Street Capital, and Mizuho. This robust financial endorsement underscores investor confidence in their mission and potential growth trajectory.
Nemaura Medical